LOGIN  |  REGISTER
Amneal Pharmaceuticals

Latest Health Technology News

VitalHub Announces Acquisition of Novari Health

July 7
Last Trade: 11.05 0.29 2.70

TORONTO, July 07, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has acquired (the “Acquisition”) Novari Health Inc. (“Novari”), a leading healthcare software provider of patient flow solutions based in Canada. Transaction Details VitalHub has acquired Novari for total up-front consideration of $43.6 million, plus potential performance-based consideration. The...Read more


PanGenomic Health Announces Financial Results for the 2024 Fiscal Year

July 2
Last Trade: 0.80 0.00 0.00

Vancouver, British Columbia, Canada – TheNewswire - July 2, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce that it has filed its audited annual consolidated financial statements for the financial year ended December 31, 2024 (the “2024 Year End Financial Statements”). The 2024 Year End Financial Statements, together with detailed information regarding the Company's financial results...Read more


Premier Expands Clinical Decision Support (CDS) Capabilities with Acquisition of IllumiCare

June 30
Last Trade: 22.10 0.08 0.36

IllumiCare’s cost attribution technology defines low-value care and makes costs transparent in real time, enabling improved financial performance. Compatible with 50-plus electronic medical record (EMR) systems, taps into a growing demand for solutions in outpatient and ambulatory settings. Unlocks potential growth opportunities across Premier’s service lines including clinical trial optimization, revenue cycle improvement and...Read more


Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

June 27
Last Trade: 20.75 -0.37 -1.75

Demonstrates the potential of SGR-1505 as a novel approach for diseases with high unmet medical need NEW YORK / Jun 27, 2025 / Business Wire / Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström macroglobulinemia that have failed at least two lines of...Read more


Veeva Systems and AWS Expand 10-Year Relationship

June 25
Last Trade: 282.42 -1.87 -0.66

AWS compute, database, and global infrastructure support Veeva’s industry cloud for life sciences PLEASANTON, Calif. & SEATTLE / Jun 25, 2025 / Business Wire / Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and Veeva Systems (NYSE: VEEV), a leading provider of software, data, and business consulting for the life sciences industry, today announced an expansion of their long-standing collaboration. Veeva...Read more


GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics

June 25
Last Trade: 89.51 -2.10 -2.29

Data demonstrates that rapid genomic testing dropped the average time to a precise genetic diagnosis from almost ten months to 13 days Despite broad utilization in the study, rapid genomic sequencing in non-critical care inpatients yielded a diagnostic rate over 42%, comparable to critical care settings Study supports broader adoption of rapid genomic testing in the non-critical care inpatient setting to improve pediatric patient...Read more


First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

June 25
Last Trade: 7.50 0.00 0.00

The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence...Read more


FDA Approves Expanded Indications for GE HealthCare’s Vizamyl PET Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer’s Patients

June 24
Last Trade: 76.40 0.33 0.43

The FDA has approved an updated label for Vizamyl (flutemetamol F 18 injection), including quantification which enables a more continuous and objective measure of amyloid in the brain This approval also enables clinicians to use Vizamyl to monitor patient response to anti-amyloid therapies Other updates include now enabling the use of Vizamyl to predict development of dementia or other cognitive decline due to Alzheimer’s disease,...Read more


Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women’s Health

June 24
Last Trade: 21.45 -0.01 -0.05

With nearly one third of women impacted by pelvic floor disorders, expanded care access and education from Progyny will help eliminate the silent suffering NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that it is adding pelvic floor therapy to its comprehensive offering of women’s health and family building solutions. With the...Read more


Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

Dr. Kris Radcliff to Highlight MR Spectroscopy and Augmented Intelligence (AI)-Based Platform at State of Spine Surgery Think Tank BROOMFIELD, Colo., June 24, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain,...Read more


OneMedNet Announces Additional $3.7 Million of Funding in Private Placement Transactions and Approximately $11 Million in Reductions in Liabilities

June 24
Last Trade: 0.55 -0.001 -0.18

MINNEAPOLIS, June 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading provider of regulatory-grade imaging Real-World Data (iRWD), today announced that it has entered into agreements with accredited investors in private placement transactions at $0.42 per share of common stock that resulted in gross proceeds of approximately $3.7 million, before deducting fees and expenses payable...Read more


OptimizeRx Appoints CEO Steve Silvestro to Board of Directors

June 24
Last Trade: 13.27 -0.17 -1.23

WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company’s Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro...Read more


GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability

June 23
Last Trade: 89.51 -2.10 -2.29

A milestone in pediatric medicine, general pediatricians are now expected to play a more active role in initiating genetic testing Earlier use of exome and genome testing delivers better clinical outcomes and reduces costs across the U.S. healthcare system1 GeneDx will lead education and adoption efforts to end the diagnostic odyssey GAITHERSBURG, Md. / Jun 23, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering...Read more


GeneDx: Galatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common Diseases

June 23
Last Trade: 89.51 -2.10 -2.29

MIAMI & OAKLAND, Calif. / Jun 23, 2025 / Business Wire / Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases. The initial offering will include an inherited cardiovascular gene panel based on American Heart Association (AHA)...Read more


NetraMark's AI Significantly Outperforms ChatGPT, DeepSeek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success

June 23
Last Trade: 1.33 0.00 0.00

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials has released a new preprint on arXiv demonstrating that its flagship AI platform, NetraAI, has substantially outperformed leading large language models, DeepSeek and ChatGPT. NetraAI also outperformed traditional...Read more


GE HealthCare enhances cardiac diagnostics with innovative molecular imaging solutions showcased at SNMMI 2025

June 23
Last Trade: 76.40 0.33 0.43

GE HealthCare continues to advance precision care in cardiology through innovative molecular imaging solutions to help support early diagnosis, tailored treatments, and improved patient outcomes. CHICAGO / Jun 23, 2025 / Business Wire / GE HealthCare’s commitment to advancing precision care in cardiology through innovative molecular imaging solutions is on full display at this week’s Society of Nuclear Medicine and Molecular Imaging...Read more


BullFrog AI’s Dr. Juan Felipe Beltrán to Highlight Advanced AI Strategies in Bioinformatics at XTalks Webinar

June 20
Last Trade: 1.54 -0.09 -5.52

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Dr. Juan Felipe Beltrán, Director of AI, Machine Learning, and Innovation, will be the featured speaker at...Read more


Pioneering precision: GE HealthCare aims to elevate clinical care through total body PET/CT technology with Stanford Medicine

June 19
Last Trade: 76.40 0.33 0.43

GE HealthCare and the Department of Radiology at Stanford Medicine aim to explore total body positron emission tomography/computed tomography (PET/CT) technology for new clinical pathways to help improve patient outcomes. Total body PET/CT technologyi is designed with the goal of supporting personalized medicine practices like theranostics, improve healthcare system efficiency, and provide scalable solutions for imaging practices and...Read more


VitalHub Completes Acquisition of Induction

June 19
Last Trade: 11.05 0.29 2.70

TORONTO, June 19, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) announced that it has completed the cash acquisition of Induction Healthcare Group PLC (“Induction”) by way of a court-sanctioned scheme of arrangement (the “Acquisition”) under Part 26 of the Companies Act 2006. For full details related to the Acquisition, please see the circular related to the scheme of arrangement...Read more


Omada Health’s Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks

June 17
Last Trade: 0 0.00 0.00

New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada’s GLP-1 companion program significantly improved persistence rates for GLP-1 medications....Read more


Waystar Appoints Aashima Gupta and Michael Roman to Board of Directors

June 16
Last Trade: 39.30 -0.04 -0.10

New directors bring deep expertise in AI innovation, healthcare, and enterprise growth LEHI, Utah and LOUISVILLE, Ky., June 16, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced the appointment of two accomplished leaders, Aashima Gupta, Global Director of Healthcare Strategy and Solutions at Google Cloud, and Michael Roman, former Executive Chairman of the...Read more


Streamline Health Solutions Reports Fiscal First Quarter 2025 Financial Results

June 16
Last Trade: 5.20 0.00 0.00

ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the fiscal first quarter of 2025 which ended April 30, 2025. Fiscal First Quarter Financial Results Total revenue for the first...Read more


Mobile-health Network Solutions Announces H1 FY2025 Results; Continues on Drive Towards Scale and Profitability

June 16
Last Trade: 1.08 -0.03 -2.70

Singapore, Singapore--(Newsfile Corp. - June 16, 2025) - Mobile-health Network Solutions (Nasdaq: MNDR) ("MNDR" or "the Company"), a leading MedTech innovator ranked among Asia-Pacific's high-growth companies, today announced financial results for the first six months of its fiscal year 2025 ("H1 FY2025"). H1 FY2025 performance: Short-term impact from transition to leaner, stronger model For the period ended December 31, 2024, the...Read more


GE HealthCare advances precision care with MIM Encore™ to deliver next-generation digital imaging and workflow solutions

June 12
Last Trade: 76.40 0.33 0.43

GE HealthCare expands precision care capabilities with its first combined software release with MIM Encore™, helping enhance digital imaging and workflow solutions across oncology, cardiology, and neurology. The software solution was designed to help tackle key healthcare challenges like improving efficiency, streamlining cross-departmental communication, and reducing manual workloads. Now powered with additional GE HealthCare features...Read more


NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations

June 12
Last Trade: 1.33 0.00 0.00

TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transforming clinical trial design in the pharmaceutical industry through streamlined access to actionable analytics uncovered by AI, today announced that NetraMark founder Dr. Joseph Geraci was the lead author on a new publication that outlines the...Read more


BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma Clients

June 12
Last Trade: 1.54 -0.09 -5.52

GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced a strategic collaboration with Sygnature Discovery, a leading UK-based contract research organization (CRO)...Read more


Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

June 12
Last Trade: 20.75 -0.37 -1.75

SGR-1505 was observed to have a favorable safety profile and was well tolerated, with encouraging preliminary efficacy in patients with relapsed/refractory B-cell malignancies Responses observed across a broad range of B-cell malignancies, including monotherapy responses in patients with CLL and Waldenström macroglobulinemia Management to host a webcast today at 8:00 a.m. ET MILAN / Jun 12, 2025 / Business Wire / Schrödinger, Inc....Read more


Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue

June 11
Last Trade: 17.26 -0.50 -2.82

Updates fiscal 2025 revenue guidance range Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET RESEARCH TRIANGLE PARK, N.C. / Jun 11, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the...Read more


Medtech Industry Establishes Foundation for Clinical Trials with Veeva Systems MedTech

June 11
Last Trade: 282.42 -1.87 -0.66

More than 50 medtech companies, including 11 of the top 20, have adopted Veeva clinical applications for greater efficiency and speed PLEASANTON, Calif., June 11, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech clinical research organizations (CROs), have selected Veeva Clinical Platform applications to...Read more


HEALWELL AI Leverages Orion Health to Power Entry into US Market

June 11
Last Trade: 1.30 -0.02 -1.52

HEALWELL launches in the U.S. market a suite of AI enabled tools to complement Orion Health's established software offerings in the U.S. This will bring together HEALWELLs globally validated AI capabilities with Orion Health's best-in-class health data infrastructure software creating a unique offering for the U.S. market. This U.S. market launch leverages Orion Health's deep U.S. sector experience, existing U.S. footprint and...Read more


Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site

June 10
Last Trade: 7.50 0.00 0.00

UHealth — University of Miami Health System and the University of Miami Miller School of Medicine provide world-class research and renowned clinical expertise in spine surgery CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS)...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE